Health Ministry expands QR code-based drug traceability to vaccines, antimicrobials, and cancer medicines

The Union Ministry of Health and Family Welfare has notified amendments to the Drugs Rules, 1945, expanding the QR code-based track-and-trace framework to fo...

What Happened

The Union Ministry of Health and Family Welfare has notified amendments to the Drugs Rules, 1945, expanding the QR code-based track-and-trace framework to four additional drug categories: vaccines, anti-cancer medicines, antimicrobials, and narcotic and psychotropic (NDPS) medicines.
All four categories are now brought under Schedule H2, which mandates barcodes or QR codes on primary (or secondary, where space is limited) packaging labels.
Manufacturers must encode information enabling authentication and verification of medicines through digital applications across the supply chain — from manufacturer to patient.
Implementation timeline: vaccines, anti-cancer drugs, and NDPS medicines must comply by July 1, 2027; antimicrobials by July 1, 2028.
The move is aimed at combating counterfeit and substandard medicines, and also supports India's fight against Antimicrobial Resistance (AMR) by enabling monitoring of spurious antimicrobial products.
The Central Drugs Standard Control Organisation (CDSCO) will oversee enforcement under the Drugs and Cosmetics Act, 1940.

Static Topic Bridges

Drugs and Cosmetics Act, 1940 and Schedule System

The Drugs and Cosmetics Act, 1940 is the primary legislation governing import, manufacture, distribution, and sale of drugs in India. It is administered jointly by the central government (through CDSCO) and state drug authorities.

The Act is operationalised through the Drugs and Cosmetics Rules, 1945, which classify medicines under distinct schedules that determine their control, labelling, and dispensing requirements:

Schedule H: Prescription-only drugs (sold only against a Registered Medical Practitioner's prescription); labelled with "Rx" symbol at top left.
Schedule H1 (notified in 2013): Higher-risk prescription drugs including third and fourth generation antibiotics, anti-TB drugs, and psychotropic drugs; pharmacists must maintain a separate register recording each sale.
Schedule H2 (the new expansion): The most tightly controlled non-narcotic category; now adds barcodes/QR codes on packaging for full supply-chain traceability. Vaccines, antimicrobials, anti-cancer, and NDPS drugs fall here.
Schedule X: Narcotic and psychotropic drugs under even stricter record-keeping (predates NDPS Act provisions).

Connection to this news: Bringing these four high-risk categories under Schedule H2 with QR code requirements represents a significant tightening of the regulatory chain, addressing gaps that allowed counterfeit drugs to enter the supply chain at multiple points.

Antimicrobial Resistance (AMR) and India's Response

Antimicrobial Resistance occurs when bacteria, viruses, fungi, and parasites evolve to resist the medicines used to treat them, rendering standard treatments ineffective. The WHO has declared AMR one of the top ten global public health threats.

India is among the world's largest consumers of antibiotics — both in human healthcare and in animal husbandry — making it particularly vulnerable to AMR. Irrational antibiotic use, availability of antibiotics over the counter without prescription, and the circulation of substandard or counterfeit antibiotics all accelerate resistance.

India's National Action Plan on AMR (NAP-AMR, 2017–2021, extended) commits to surveillance, stewardship, and containment.
The Schedule H1 amendment (2013) first attempted to curb over-the-counter antibiotic sales by requiring pharmacy registers.
Global AMR burden: an estimated 1.27 million deaths directly attributed to AMR annually worldwide (Lancet, 2022).
Counterfeit or substandard antibiotics are a dual problem: they fail to cure infections AND expose bacteria to sub-therapeutic doses, accelerating resistance.

Connection to this news: QR code traceability for antimicrobials directly addresses the substandard/counterfeit drug pathway to AMR by enabling real-time verification of a product's manufacturing origin, batch, and authenticity at every point of sale.

Track-and-Trace Systems in Drug Regulation: Global and Indian Context

Track-and-trace (T&T) refers to the ability to follow a drug's journey from manufacturer to patient and to locate ("trace") it at any point in that chain. Most major pharmaceutical markets now require serialisation of drug packaging — a unique identifier per unit.

The US Drug Supply Chain Security Act (DSCSA, 2013) mandated unit-level serialisation, with full interoperability required by November 2024.
The EU Falsified Medicines Directive (2011/62/EU) mandated unique identifiers and tamper-evident features on prescription medicines packaging across the EU.
In India, QR code-based traceability was first introduced for 300 high-value formulations (including cardiovascular, anti-diabetic, and immunosuppressant drugs) before the current expansion.
CDSCO operates the Central Drug Laboratory (CDL) for quality testing and oversees market surveillance.

Connection to this news: India's expansion of QR codes to vaccines and cancer drugs brings it in line with global best practices. Given India's status as the world's largest vaccine producer ("Pharmacy of the World"), traceability of vaccines is especially critical for export credibility and domestic public health.

Counterfeit Medicines: Scale and Consequences

Counterfeit and substandard medicines are a significant public health and economic problem. WHO estimates that 1 in 10 medical products in low- and middle-income countries is substandard or falsified.

In India, surveys have found substandard drug rates in the range of 3–8% in some studies, with "not of standard quality" (NSQ) alerts issued regularly by CDSCO.
The economic cost of counterfeit medicines globally is estimated at over $200 billion annually.
Counterfeit cancer drugs and vaccines carry immediate life-threatening risks: a patient receiving a fake cancer drug may receive no active ingredient, allowing cancer to progress; a counterfeit vaccine provides no protection and may cause harm.
QR codes enable patients, pharmacists, and regulators to verify authenticity at the point of dispensing via a smartphone scan.

Connection to this news: The specific inclusion of vaccines and anti-cancer drugs — two categories where a substandard product can be immediately life-threatening — signals the government's prioritisation of the highest-risk segments for the first phase of implementation (July 2027).

Key Facts & Data

Legislation: Drugs and Cosmetics Act, 1940; Drugs and Cosmetics Rules, 1945 (amended June 2026).
New categories under Schedule H2: vaccines, anti-cancer drugs, antimicrobials, narcotic and psychotropic (NDPS) substances.
Compliance deadline: vaccines, anti-cancer, NDPS — July 1, 2027; antimicrobials — July 1, 2028.
Mechanism: barcode or QR code on primary packaging (or secondary where space is limited), enabling software-based authentication across the supply chain.
Regulator: Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare.
India is the world's largest vaccine producer by volume (Serum Institute of India alone accounts for ~60% of global vaccine doses).
WHO estimates 1 in 10 medical products in LMICs is substandard or falsified.
India's National Action Plan on Antimicrobial Resistance (NAP-AMR) identifies monitoring of substandard antimicrobials as a key containment strategy.